{"id":43404,"date":"2024-08-05T12:00:00","date_gmt":"2024-08-05T10:00:00","guid":{"rendered":"https:\/\/kapitalpartner.dk\/?p=43404"},"modified":"2024-08-20T12:00:47","modified_gmt":"2024-08-20T10:00:47","slug":"sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own","status":"publish","type":"post","link":"https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/","title":{"rendered":"Sector up 41% YTD, EIS best performer, more reverse mergers, Gubra in league of their own"},"content":{"rendered":"\n

NORDIC | BIOTECH & HEALTHCARE<\/strong> Your insights into listed Danish & Nordic biotech & healthcare stocks.<\/em><\/p>\n\n\n\n

Last week the Nordic healthcare stocks fell 3.1%, while the Danish healthcare stocks had a <\/strong>0.7% decline<\/strong>. Cessatech outlined its key priorities for the rest of 2024, Genmab received price targets, and CS Medica fell 17% after more than doubling. The Danish biotech stocks have on average increased 41% year-to-date.<\/strong><\/p>\n\n\n\n

9 of the 22 Danish biotech companies had a positive share price development the past week and 11 companies have had a positive share price performance year-to-date.<\/strong> Gubra is the best-performing Danish healthcare stock year-to-date with a 433% return and European Institute of Science AB<\/strong> was the best Nordic healthcare investment last week.<\/strong> 5 Danish healthcare stocks with +100% YTD return.<\/strong><\/p>\n\n\n\n

<\/p>\n\n\n\n

\n
Register for the Nordic I Impact newsletter here.<\/strong><\/a><\/div>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

Danish company news<\/strong><\/p>\n\n\n\n

Acarix<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Ascendis Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/p>\n\n\n\n

Biosergen<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Cessatech<\/a><\/strong><\/p>\n\n\n\n

Key Cessatech priorities for the rest of the year (Link<\/a>)<\/p>\n\n\n\n

CS Medica<\/a><\/strong><\/p>\n\n\n\n

CS MEDICA’s Subsidiary, CANNORDIC, Signs Distributor Partnership with PHARMALINK (Link<\/a>)<\/p>\n\n\n\n

CS MEDICA’s View of the Evolving European CBD Market (Link<\/a>)<\/p>\n\n\n\n

Curasight<\/a><\/strong><\/p>\n\n\n\n

Curasight issues warrants as part of long-term incentive program (Link<\/a>)<\/p>\n\n\n\n

DanCann Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Evaxion Biotech<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/p>\n\n\n\n

ExpreS2ion<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Fluoguide<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Genmab<\/a><\/strong><\/p>\n\n\n\n

Jyske Bank lowered their price target from DKK 2,850 to DKK 2,600 and Carnegie from DKK 2,720 to DKK 2,760<\/p>\n\n\n\n

Gubra<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Initiator Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

IO Biotech<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/p>\n\n\n\n

Pila Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Saniona<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Scandion Oncology<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/p>\n\n\n\n

SynAct Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/p>\n\n\n\n

ViroGates<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Zealand Pharma<\/a><\/strong><\/p>\n\n\n\n

Zealand Pharma Appoints Eric Cox as Chief Commercial Officer<\/em><\/p>\n\n\n\n

Y-mAbs Therapeutics<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/p>\n\n\n\n

2cureX<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/p>\n\n\n\n

Share price development – Danish stocks<\/strong><\/p>\n\n\n\n

On average, the Danish biotech and healthcare stocks delivered a poor performance with a return of -0.7%. Biosergen<\/a><\/strong> became the best-performing stock without any news to report. Cessatech<\/a><\/strong> also performed well following communication of their key priorities in 2024. Furthermore, Genmab<\/a><\/strong> got updated price targets, and CS Medica<\/a><\/strong> fell 17% although they signed a new distribution agreement with PHARMALINK. However, it should be noted that CS Medica is still up more than 100% in the past month.<\/p>\n\n\n\n

The best stock year-to-date is Gubra<\/a><\/strong> followed by <\/a><\/a>Pila Pharma<\/a><\/strong><\/strong><\/strong><\/strong> with 433% and 309% increases respectively after the first 6 months of trading. CS Medica<\/a><\/strong>, Zealand Pharma<\/a>,<\/strong> and <\/a>Acarix<\/a><\/strong><\/strong> have also made a +136% to 164% return year-to-date. Overall the Danish biotech and healthcare stocks are in positive territory this year with a year-to-date return of 41%. In other words, it has had a stellar performance.<\/strong><\/p>\n\n\n\n

Overview of share price development the past week, year-to-date, and the last twelve months<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Nordic Biotech & Healthcare Developments<\/mark><\/strong><\/p>\n\n\n\n

In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC)<\/strong> fell 3.1% to 68,86. The index has had a strong performance since the end of April and it has now surpassed the KPNGX index. In the past 12 months, the KPHC index has significantly underperformed relative to large caps, while the venture\/small cap Kapital Partner Nordic Growth Exchanges index (KPNGX) has followed the KPHC index’s downward trajectory down around 10%.<\/p>\n\n\n\n

The index development for the KPHC index the past year<\/strong><\/p>\n\n\n\n

\"\"
The KPHC index includes all Nordic healthcare stocks. This means both Novo Nordisk and Genmab as well as Curasight.<\/sup><\/figcaption><\/figure>\n\n\n\n

53-87% in weekly return for the Nordic healthcare stocks<\/strong><\/p>\n\n\n\n

European Institute of Science AB<\/a><\/strong> (87%)<\/strong> share price rose following news of a reverse acquisition of Apotek365.<\/p>\n\n\n\n

Immunovia<\/a> (67%)<\/strong> is focused on molecular diagnostics, where the business focuses on driving the development and change of current working methods for diagnosing complex cancers and immune diseases. The vision is to establish blood-based tests to be able to identify different types of pancreatic cancer at an early stage. The share price rose following of significant improvements in their pipeline (Link<\/a>).<\/p>\n\n\n\n

Alzinova <\/a>(53%) <\/strong>specializes in the therapeutic treatment of Alzheimer’s and conducts research and development of peptides that are further developed as vaccines. In addition, the company also develops various research tools in the work area. The largest operations are in the Nordic market.<\/p>\n\n\n\n

Sources: Refinitiv Eikon, Cision, Nordnet & company websites.<\/strong><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. Last week the Nordic healthcare stocks fell 3.1%, while the Danish healthcare stocks had a 0.7% decline. Cessatech outlined its key priorities for the rest of 2024, Genmab received price targets, and CS Medica fell 17% after more than doubling. […]<\/p>\n","protected":false},"author":11,"featured_media":43132,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[29],"tags":[],"class_list":["post-43404","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investeringscases"],"acf":[],"yoast_head":"\nSector up 41% YTD, EIS best performer, more reverse mergers, Gubra in league of their own | Kapital Partner A\/S<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sector up 41% YTD, EIS best performer, more reverse mergers, Gubra in league of their own | Kapital Partner A\/S\" \/>\n<meta property=\"og:description\" content=\"NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. Last week the Nordic healthcare stocks fell 3.1%, while the Danish healthcare stocks had a 0.7% decline. Cessatech outlined its key priorities for the rest of 2024, Genmab received price targets, and CS Medica fell 17% after more than doubling. […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/\" \/>\n<meta property=\"og:site_name\" content=\"Kapital Partner A\/S\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kapitalpartner\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-05T10:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-20T10:00:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"724\" \/>\n\t<meta property=\"og:image:height\" content=\"418\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Anders S\u00f8ndergaard\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:site\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anders S\u00f8ndergaard\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/\"},\"author\":{\"name\":\"Anders S\u00f8ndergaard\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\"},\"headline\":\"Sector up 41% YTD, EIS best performer, more reverse mergers, Gubra in league of their own\",\"datePublished\":\"2024-08-05T10:00:00+00:00\",\"dateModified\":\"2024-08-20T10:00:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/\"},\"wordCount\":726,\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"articleSection\":[\"Investeringscases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/\",\"url\":\"https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/\",\"name\":\"Sector up 41% YTD, EIS best performer, more reverse mergers, Gubra in league of their own | Kapital Partner A\/S\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"datePublished\":\"2024-08-05T10:00:00+00:00\",\"dateModified\":\"2024-08-20T10:00:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/#primaryimage\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"width\":724,\"height\":418},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investeringscases\",\"item\":\"https:\/\/kapitalpartner.dk\/category\/investeringscases\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Sector up 41% YTD, EIS best performer, more reverse mergers, Gubra in league of their own\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kapitalpartner.dk\/#website\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"name\":\"Kapital Partner A\/S\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kapitalpartner.dk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\",\"name\":\"Kapital Partner A\/S\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"width\":496,\"height\":432,\"caption\":\"Kapital Partner A\/S\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/kapitalpartner\",\"https:\/\/x.com\/KapitalPartner\",\"https:\/\/www.linkedin.com\/company\/10438322\",\"https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\",\"name\":\"Anders S\u00f8ndergaard\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"caption\":\"Anders S\u00f8ndergaard\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sector up 41% YTD, EIS best performer, more reverse mergers, Gubra in league of their own | Kapital Partner A\/S","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/","og_locale":"en_US","og_type":"article","og_title":"Sector up 41% YTD, EIS best performer, more reverse mergers, Gubra in league of their own | Kapital Partner A\/S","og_description":"NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. Last week the Nordic healthcare stocks fell 3.1%, while the Danish healthcare stocks had a 0.7% decline. Cessatech outlined its key priorities for the rest of 2024, Genmab received price targets, and CS Medica fell 17% after more than doubling. […]","og_url":"https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/","og_site_name":"Kapital Partner A\/S","article_publisher":"https:\/\/www.facebook.com\/kapitalpartner","article_published_time":"2024-08-05T10:00:00+00:00","article_modified_time":"2024-08-20T10:00:47+00:00","og_image":[{"width":724,"height":418,"url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","type":"image\/jpeg"}],"author":"Anders S\u00f8ndergaard","twitter_card":"summary_large_image","twitter_creator":"@KapitalPartner","twitter_site":"@KapitalPartner","twitter_misc":{"Written by":"Anders S\u00f8ndergaard","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/#article","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/"},"author":{"name":"Anders S\u00f8ndergaard","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed"},"headline":"Sector up 41% YTD, EIS best performer, more reverse mergers, Gubra in league of their own","datePublished":"2024-08-05T10:00:00+00:00","dateModified":"2024-08-20T10:00:47+00:00","mainEntityOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/"},"wordCount":726,"publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","articleSection":["Investeringscases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/","url":"https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/","name":"Sector up 41% YTD, EIS best performer, more reverse mergers, Gubra in league of their own | Kapital Partner A\/S","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/#primaryimage"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","datePublished":"2024-08-05T10:00:00+00:00","dateModified":"2024-08-20T10:00:47+00:00","breadcrumb":{"@id":"https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/#primaryimage","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","width":724,"height":418},{"@type":"BreadcrumbList","@id":"https:\/\/kapitalpartner.dk\/en\/sector-up-41-ytd-eis-best-performer-more-reverse-mergers-gubra-in-league-of-their-own\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kapitalpartner.dk\/en\/"},{"@type":"ListItem","position":2,"name":"Investeringscases","item":"https:\/\/kapitalpartner.dk\/category\/investeringscases\/"},{"@type":"ListItem","position":3,"name":"Sector up 41% YTD, EIS best performer, more reverse mergers, Gubra in league of their own"}]},{"@type":"WebSite","@id":"https:\/\/kapitalpartner.dk\/#website","url":"https:\/\/kapitalpartner.dk\/","name":"Kapital Partner A\/S","description":"","publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kapitalpartner.dk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kapitalpartner.dk\/#organization","name":"Kapital Partner A\/S","url":"https:\/\/kapitalpartner.dk\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","width":496,"height":432,"caption":"Kapital Partner A\/S"},"image":{"@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kapitalpartner","https:\/\/x.com\/KapitalPartner","https:\/\/www.linkedin.com\/company\/10438322","https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w"]},{"@type":"Person","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed","name":"Anders S\u00f8ndergaard","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","caption":"Anders S\u00f8ndergaard"}}]}},"_links":{"self":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/43404"}],"collection":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/comments?post=43404"}],"version-history":[{"count":1,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/43404\/revisions"}],"predecessor-version":[{"id":43406,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/43404\/revisions\/43406"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media\/43132"}],"wp:attachment":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media?parent=43404"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/categories?post=43404"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/tags?post=43404"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}